USP Bioburden Update: New Chapters <1119> and & <1119.1>
The United States Pharmacopeia (USP) has introduced changes to how bioburden testing and monitoring are addressed in pharmaceutical microbiology. Historically, microbiologists relied on indirect guidance from multiple chapters such as <61>, <1111>, and <1229.3>.
However, USP recognized that the existing structure did not provide clear guidance for bioburden testing across different pharmaceutical materials. To address this gap, USP introduced two dedicated chapters:
USP <1119> – Bioburden Monitoring
USP <1119.1> – Bioburden Test
These chapters became official on December 1, 2025. They represent a major shift toward a risk-based and process-understanding approach to microbial contamination control.
What is Bioburden?
Bioburden refers to the total number of viable microorganisms present on a material or product before sterilization or during manufacturing.
These microorganisms may originate from:
Raw materials
Manufacturing environment
Equipment
Personnel
Water systems
Packaging materials
Bioburden monitoring is especially critical in sterile manufacturing, terminal sterilization processes, API production, and primary packaging components.
The objective is not always to eliminate microorganisms, but to control them within acceptable limits so they do not compromise product safety or sterilization processes.
The Problem with the Old USP Structure
Before this update, bioburden testing guidance was given in multiple chapters.
USP ChapterPurpose<61> Microbial Enumeration TestsUsed for testing finished non-sterile products<1111> Microbiological Acceptance CriteriaDefines microbial limits<1229.3> Monitoring of BioburdenProvided general guidance on monitoring<1115> Bioburden Control of Nonsterile Drug SubstancesRisk-based control concepts
Many laboratories incorrectly used USP <61> as a generic bioburden test, even though it was designed only for release testing of non-sterile products.
Additionally, <1229.3> suggested using modified <61> methods, but it did not provide detailed instructions. There was no standardized method for bioburden testing across different sample types.
This created inconsistent practices across the industry.
Overview of the New USP Bioburden Chapters
1. USP <1119> – Bioburden Monitoring
This new chapter focuses on designing and implementing a bioburden monitoring program.
It includes guidance on:
Sampling strategies
Testing frequency
Recommended limits
Risk assessment
Monitoring of in-process materials
The chapter emphasizes a risk-based approach to monitoring microbial contamination.
2. USP <1119.1> – Bioburden Test
This chapter provides a standardized method for bioburden testing.
Key aspects include:
Enumeration of mesophilic aerobic microorganisms
Procedures for sample preparation
Methods for plating and counting CFUs
Guidance on adapting tests for different microbial populations
The chapter clarifies that bioburden testing is not the same as microbial enumeration testing (<61>) and should not be treated as such. It means bioburden testing and USP <61> microbial enumeration testing have different purposes, even though both count microorganisms.
In simple terms, Bioburden Testing as per USP <1119.1> is to measure microbial contamination present in materials before sterilization or during manufacturing, such as raw materials, APIs, water, or in-process samples, unlike the USP <61>.
The USP <61> is about finished non-sterile pharmaceutical products to ensure they meet microbial limit specifications before release.
USP <61>Bioburden Test (<1119.1>)PurposeRelease testingProcess monitoringStageFinished non-sterile productsRaw materials / in-process / pre-sterilizationGoalCheck compliance with limitsUnderstand and control contamination
Practical Impact on Pharmaceutical Microbiology Labs
Pharmaceutical microbiology laboratories should review existing bioburden test methods and revise them to align with <1119.1>.
Companies may need to implement formal risk assessments for bioburden monitoring.
Sampling plans for APIs, water, and in-process material may require updates.
Laboratories referencing USP <1229.3> should update SOPs to reference <1119> and <1119.1>.
The introduction of USP <1119> and <1119.1> reinforces the industry's move toward risk-based microbial contamination control to ensure more scientifically justified pharmaceutical manufacturing processes.
Types of Rapid Microbiological Methods (RMMs) in the Pharmaceutical Industry
Selecting Surfaces for Disinfectant Efficacy Testing in the Pharmaceutical Industry
Microorganisms of Concern vs Objectionable Microorganisms in Pharmaceuticals
Soybean Casein Digest Medium (SCDM) and Its Role in Media Fills
Five Essential Microbiology Lab Practices to Prevent Cross-Contamination